Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesIncyte Corporation

Incyte Corporation

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
119.65 USD 1.64 ( 1.39%)
Last update at 2026-11-06T21:12:00Z
VOLUME
1486110
Market Cap
24676.42M
P/E
15.57

Momentum Score

…

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
115.00
Low
119.72
High
52 Week Price Range
81.09
Low
132.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Incyte Corporation develops and commercializes therapies in oncology and hematology, combining an established marketed franchise with an active R&D pipeline. Long-term growth could be driven by label expansions, international rollout of existing medicines, and late-stage pipeline progress; these elements may appeal to investors seeking specialty oncology exposure with recurring product revenue and pipeline upside.
Key risks include dependence on a small number of marketed products, clinical and regulatory setbacks in the pipeline, pricing and reimbursement pressure, and high R&D spending that may strain margins and cash flow.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
118.01
Dividend Yield
-
Revenue TTM
5819.53M
Revenue Per Share
29.36
Gross Profit TTM
3239.07M
Debt / Equity
0.01
ROE
30.67%
Net Debt
-3028.39M
ROCE
30.63%
Diluted EPS TTM
7.82

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 1664.45M 316.63M 834.22M 529.12M 570.44M
Net income 1286.65M 32.62M 597.60M 340.66M 948.58M
Selling general administrative 1376.20M 1222.00M 1161.30M 1002.10M 739.60M
Selling and marketing expenses - 20.16M 5.64M 0.04M -0.04M
Gross profit 4769.14M 3929.12M 3440.66M 3187.64M 2835.28M
Reconciled depreciation 93.29M 89.25M 79.12M 67.86M 57.84M
Ebit 1666.88M 318.91M 836.77M 579.44M 585.78M
Ebitda 1760.16M 408.16M 919.43M 631.52M 611.16M
Depreciation and amortization 93.29M 89.25M 82.66M 52.08M 25.39M
Non operating income net other - - - 39.93M 10.65M
Operating income 1342.79M 101.29M 655.36M 579.44M 585.78M
Other operating expenses 3798.45M 4139.92M 3040.29M 2803.05M 2385.75M
Interest expense 2.43M 2.28M 2.55M 2.67M 1.91M
Tax provision 377.80M 284.01M 218.89M 188.46M -378.14M
Interest income 105.60M 128.71M 172.35M - -
Net interest income 103.17M 126.43M 106.20M -2.67M -1.91M
Income tax expense 377.80M 284.01M 236.62M 188.46M -378.14M
Total revenue 5141.24M 4241.22M 3695.65M 3394.64M 2986.27M
Total operating expenses 3426.35M 3827.82M 2785.30M 2596.05M 2234.76M
Cost of revenue 372.10M 312.10M 254.99M 207.00M 150.99M
Total other income expense net 321.66M 215.34M 178.86M -50.32M -15.33M
Net income from continuing ops 1286.65M 32.62M 424.98M 340.66M 948.58M
Net income applicable to common shares - - - 340.66M 948.58M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 6957.97M 5444.32M 6782.11M 5840.98M 4933.35M
Intangible assets 117.13M 113.80M 123.55M 129.22M 150.75M
Other current assets 317.83M 168.91M 182.83M 167.01M 165.30M
Total liab 1803.37M 1996.69M 1592.27M 1470.87M 1163.35M
Total stockholder equity 5167.48M 3447.63M 5189.84M 4370.12M 3770.00M
Other current liab 1295.02M 1416.18M 111.75M 469.74M 82.76M
Common stock 0.20M 0.19M 0.22M 0.22M 0.22M
Capital stock 0.20M 0.19M 0.22M 0.22M 0.22M
Retained earnings 213.77M -1072.88M 160.38M -437.21M -777.87M
Other liab - - - 269.60M 244.00M
Good will 133.00M 155.59M 155.59M 155.59M 155.59M
Other assets 385.84M - - 564.04M 467.54M
Cash 3097.82M 1687.83M 3213.38M 2951.42M 2057.44M
Total current liabilities 1515.17M 1641.85M 1240.38M 1216.60M 885.08M
Current deferred revenue - - 1009.91M 457.94M 617.02M
Net debt -3028.39M -1644.29M -3175.09M -2906.79M -2023.17M
Short term debt 10.21M 10.00M 9.12M 11.37M 13.19M
Short long term debt total 69.43M 37.96M 38.29M 44.64M 34.27M
Other stockholder equity 4928.05M 4533.44M 5016.12M 4792.04M 4567.11M
Property plant equipment - - - 739.31M 723.92M
Total current assets 5023.90M 3239.03M 4645.40M 4198.95M 3186.73M
Long term investments 47.99M 18.81M 187.72M 133.68M 221.27M
Net tangible assets - - - 4085.31M 3463.66M
Short term investments 482.79M 470.26M 442.67M 287.54M 290.75M
Net receivables 1024.41M 853.15M 743.56M 644.88M 616.30M
Long term debt - 33.54M - - -
Inventory 101.06M 58.87M 62.97M 120.96M 56.94M
Accounts payable 209.94M 197.47M 109.60M 277.55M 172.11M
Accumulated other comprehensive income 25.46M -13.12M 13.11M 15.07M -19.45M
Common stock total equity - - - 0.22M 0.22M
Retained earnings total equity - - - -437.21M -777.87M
Non currrent assets other -47.99M 360.80M 260.92M 106.10M 68.06M
Non current assets total 1523.83M 2205.29M 2136.70M 1642.04M 1746.62M
Capital lease obligations 40.41M 43.54M 38.29M 41.46M 44.82M
Long term debt total - 33.54M - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -18.74M 157.52M -74.09M -0.71M -26.69M
Change to liabilities - - - 325.63M 204.78M
Total cashflows from investing activities -102.61M 157.52M -207.68M -78.54M -207.70M
Net borrowings -4.54M -3.80M -3.36M -2.86M -2.42M
Total cash from financing activities 101.04M -2021.55M -20.03M -0.79M 6.18M
Change to operating activities - - - 189.46M 67.36M
Net income 1286.65M 32.62M 597.60M 340.66M 948.58M
Change in cash 1410.22M -1525.77M 262.10M 893.96M 544.39M
Begin period cash flow 1689.45M 3215.22M 2953.12M 2059.16M 1514.77M
End period cash flow 3099.67M 1689.45M 3215.22M 2953.12M 2059.16M
Total cash from operating activities 1413.50M 335.34M 496.49M 969.94M 749.49M
Depreciation 93.29M 89.25M 82.66M 67.86M 57.84M
Other cashflows from investing activities -25.00M -13.90M -47.49M - -
Change to inventory -58.51M -127.63M -170.15M -67.50M -20.96M
Change to account receivables -170.77M -111.59M -98.68M -28.58M -134.31M
Sale purchase of stock -19.10M -2004.79M -28.55M 61.12M 58.63M
Other cashflows from financing activities -97.08M -62.26M -52.51M -59.05M -50.03M
Change to netincome - - - 275.03M -266.44M
Capital expenditures 58.87M 86.26M 47.49M 77.83M 181.01M
Change receivables - - - -28.58M -134.31M
Cash flows other operating - - - 56.85M -40.01M
Cash and cash equivalents changes - - - 890.61M 547.97M
Change in working capital -527.16M 138.24M -248.65M 198.81M -14.57M
Stock based compensation 249.35M 266.06M 215.89M 188.42M 183.01M
Other non cash items 63.69M -105.28M 7.89M 117.11M 40.23M
Free cash flow 1354.63M 249.07M 449.00M 892.11M 568.48M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
INCY
Incyte Corporation		 1.64
1.39%		 119.65 15.57 14.16 4.24 3.90 3.48 9.80
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Incyte Corporation

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

1801 Augustine Cut-Off, Wilmington, DE, United States, 19803

302 498 6700

https://www.incyte.com

2844

Name Title Year Born
Mr. Herve Hoppenot Chairman, Pres & CEO 1960
Ms. Christiana Stamoulis MBA Exec. VP & CFO 1971
Ms. Maria E. Pasquale J.D. Exec. VP, Gen. Counsel & Corp. Sec. 1966
Dr. Barry P. Flannelly M.B.A., MBA, Pharm.D. Exec. VP & GM of North America 1958
Dr. Steven H. Stein M.D. Exec. VP & Chief Medical Officer 1967
Mr. Thomas Tray VP of Fin., Chief Accounting Officer & Controller 1978
Mr. Michael James Morrissey Exec. VP & Head of Global Technical Operations 1964
Dr. Dashyant Dhanak Ph.D. Exec. VP & Chief Scientific Officer 1961
Ms. Christine Chiou Head of Investor Relations NA
Ms. Pamela M. Murphy VP of Investor Relations & Corp. Communications 1951

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…